Velcade (Bortezomib) Reconstitution
Bortezomib must be reconstituted differently depending on the route of administration: for subcutaneous injection, add 1.4 mL of 0.9% sodium chloride to achieve a final concentration of 2.5 mg/mL; for intravenous injection, add 3.5 mL of 0.9% sodium chloride to achieve a final concentration of 1 mg/mL. 1
Reconstitution Procedure by Route
Subcutaneous Administration (Preferred Route)
- Add 1.4 mL of 0.9% sodium chloride to the 3.5 mg vial 1
- Final concentration: 2.5 mg/mL 1
- Subcutaneous administration is the preferred method as it significantly reduces peripheral neuropathy rates (grade 3/4 neuropathy reduced to 6-7%) while maintaining equivalent efficacy compared to intravenous delivery 2, 3
- The subcutaneous route reduces the incidence of grade 3 or higher thrombocytopenia and bortezomib-induced peripheral neuropathy compared to IV administration 4
Intravenous Administration
- Add 3.5 mL of 0.9% sodium chloride to the 3.5 mg vial 1
- Final concentration: 1 mg/mL 1
- This route should be reserved for patients who cannot receive subcutaneous injections (e.g., those with significant thrombocytopenia) 2
Storage and Stability Considerations
Immediate Use Guidelines
- Once reconstituted, the manufacturer recommends using within 3 hours in a syringe or 8 hours in a vial 5
- Store protected from light at room temperature during this period 5
Extended Storage (If Necessary)
- Research demonstrates that bortezomib solution (1 mg/mL) stored refrigerated at 5°C and protected from light maintains >95% concentration for 5 days in both vials and syringes 5
- Oxidation, light exposure, and storage temperature all affect chemical stability 5
- There is no color change, precipitation, or pH instability during this extended storage period 5
Practical Administration Details
Volume Considerations for Subcutaneous Injection
- The standard maximum volume per subcutaneous injection site is typically 2 mL, but volumes up to 3 mL per injection site are well tolerated with limited skin reactions 6
- Using 3 mL as the maximum volume reduces the need for multiple injections per visit (only 5 patients out of 57 required two injections when using 3 mL maximum versus 46 patients who would have needed two injections with a 2 mL maximum) 6
- Skin reactions occur in approximately 42% of patients but are limited to Grade 1 or 2 severity 6
Critical Safety Measures During Bortezomib Therapy
Mandatory Prophylaxis
- All patients must receive herpes zoster prophylaxis (acyclovir or valacyclovir) throughout the entire treatment course 2, 3, 7
- Consider PJP prophylaxis when bortezomib is combined with rituximab-containing regimens 2
Dosing Schedule Optimization
- Weekly dosing is preferred over twice-weekly schedules as it maintains efficacy (ORR 93% vs 88%) while reducing grade 3/4 adverse events (37%/3% vs 48%/12%) and requires fewer dose reductions 2, 3
- Typical dosing: bortezomib 1.3 mg/m² subcutaneously on days 1,8,15, and 22 of a 21-28 day cycle 2, 7
Monitoring Requirements
- Peripheral neuropathy is the key dose-limiting toxicity, occurring in 35-47% of patients overall with grade 3/4 severity in 8-13% 3
- Patients with pre-existing neuropathy should avoid bortezomib or receive attenuated dosing 2, 3
- Dose reductions are recommended for patients experiencing peripheral neuropathy, grade 3 or higher non-hematologic toxicities, or grade 4 hematologic toxicities 8, 9